TABLE 4.

Risk factors associated with the persistence of pulmonary sequela in the overall population (n = 347).

	Univariable analysis	p	Multivariable analysis	p
	OR (95% CI)		OR (95% CI)
Demographics
Age ≥ 63 years	2.8 (1.09–7.33)	0.03	2.6 (0.96–7.18)	0.06
BMI ≥ 27 kg/m2	0.4 (0.15–1.07)	0.07
Smoking history
Current smoker–yes	5.2 (1.53–17.53)	0.008	5.6 (1.41–22.12)	0.01
No-smoker–yes	2.0 (0.86–4.58)	0.11
Comorbidities
Cardiovascular disease–yes	1.2 (0.52–2.73)	0.68
Respiratory disease–yes	2.1 (0.79–5.61)	0.13
Autoimmune disease–yes	2.5 (0.99–6.48)	0.051
Metabolic disease–yes	1.0 (0.44–2.33)	0.98
Oncologic disease–yes	1.4 (0.49–3.84)	0.55
Hospitalization characteristics
Hospitalization time ≥ 10 days	2.9 (1.14–7.61)	0.03	1.0 (0.25–3.29)	0.89
High degree of care–yes	4.7 (1.99–10.92)	0.0001	2.6 (0.83–8.35)	0.10
FiO2 max. ≥ 36%	2.6 (1.01–6.78)	0.047	1.1 (0.31–3.86)	0.89
PaO2/FiO2 ≥ 295	0.4 (0.14–1.25)	0.12
Treatment during hospitalization
Hydroxychloroquine/chloroquine–yes	1.4 (0.61–3.24)	0.42
Azithromycin–yes	0.7 (0.33–1.75)	0.52
Ceftriaxone–yes	1.1 (0.44–2.38)	0.95
Other antibiotics–yes	3.6 (1.54–8.61)	0.003	2.4 (0.84–3.28)	0.10
Lopinavir/ritonavir–yes	1.9 (0.74–4.73)	0.18
Remdesivir–yes	1.4 (0.58–3.24)	0.47
Other antiviral–yes	2.7 (0.31–24.6)	0.36
Tocilizumab–yes	2.9 (0.78–10.9)	0.11
Corticosteroids–yes	3.4 (0.98–11.6)	0.052
Heparins–yes	0.88 (0.32–2.46)	0.81
Corticosteroids during follow-up–yes	1.8 (0.74–4.59)	0.19

BMI: body mass index.